

Haematologica
HAEMATOL/2018/211110
Version 3

Histone deacetylase inhibition in combination with MEK or BCL-2
inhibition in multiple myeloma

Vijay G. Ramakrishnan, Kevin C. Miller, Elaine P. Macon, Teresa K.
Kimlinger, Jessica Haug, Sanjay Kumar, Wilson I. Gonsalves, S.
Vincent Rajkumar, and Shaji K. Kumar

Disclosures: Shaji Kumar has been a non-paid consultant or advisory board member for AbbVie, Celgene, Janssen, Kite Pharma, Merck, and Takeda and is the Principal Investigator in clinical trials supported by Bristol-Myers Squibb, Celgene, Janssen, Kite Pharma, Roche/Genentech, Sanofi, and Takeda. The other authors report no conflicts of interest.

Contributions: V.G.R., K.C.M., S.K.K designed experiments. V.G.R., K.C.M., E.P.M., T.K.K., J.L.H., S.K., and W.I.G. performed experiments. V.G.R and K.C.M. wrote initial draft of manuscript. V.G.R., S.V.R. and S.K.K. provided funding and all authors reviewed the manuscript.